Study on the oxidative stress status among cement plant workers

2008 ◽  
Vol 27 (6) ◽  
pp. 463-469 ◽  
Author(s):  
S Pournourmohammadi ◽  
P Khazaeli ◽  
S Eslamizad ◽  
A Tajvar ◽  
A Mohammadirad ◽  
...  
Keyword(s):  
Chronic Disease ◽  
Serum Level ◽  
Serum Levels ◽  
Cement Industry ◽  
Healthy Control Group ◽  
Control Group ◽  
Exposure Group ◽  
Exposed Workers ◽  
Indirect Exposure ◽  
Healthy Control

The cement industry is considered as a major pollution problem because of dust and particulate matter emitted at various steps of cement production. In the present study, volunteer male workers from a cement factory were studied for oxidative and nitrosative stress biomarkers in relation to their serum levels of aluminum (Al) and chromium (Cr). The subjects were divided into two groups of direct and indirect exposure. Subject who worked in production steps were considered as direct exposure group, and those who worked in administration building were considered as indirect exposure group. For comparison, healthy subjects at the same age and socioeconomic status were tested as a control group. Serum levels of lipid peroxidation (LP), total antioxidant capacity (TAC), total thiol molecules (TTM), and nitric oxide (NO) as well as Al and Cr were measured. The results indicated a significant increase in Al ( P = 0.001) and Cr ( P = 0.009) levels in direct-exposed workers in comparison to healthy control group. Further, a significant increase in Al ( P = 0.002) and Cr ( P = 0.009) levels was observed in direct-exposed workers as compared to indirect-exposed one. Serum levels of TTM and TAC were significantly lower in both direct- and indirect-exposed groups in comparison to healthy control group ( P = 0.00). Serum TTM and TAC were significantly lower in direct-exposed workers as compared to indirect-exposed ones ( P = 0.00 and P = 0.024, respectively). There was no significant difference on the level of LP and NO among groups. A correlation was found between serum level of Cr, TAC, and platelets between direct- and indirect-exposed groups ( P < 0.05). Further correlation was found among serum level of Cr and those of TTM, platelets, and chronic disease ( P < 0.05). Chronic disease had a significant influence adjusted to other predictor variables on the post-shift values of Al ( P < 0.05). Although plasma levels of Al and Cr were found in normal ranges, analyses confirm their role in impairment of TMM and TAC.

scholarly journals Evaluation the Serum Level of Sex Hormones in Patients With Trigeminal Neuralgia

2021 ◽  
Author(s):  
Fatemeh Lavaee ◽  
Parisa Mohaghegh Zahed ◽  
Fateme Zarei ◽  
Maryam Shahrokhi Sardo
Keyword(s):  
Serum Level ◽  
Trigeminal Neuralgia ◽  
Sex Hormones ◽  
Menopausal Status ◽  
Serum Levels ◽  
Sex Hormone ◽  
Healthy Control Group ◽  
Control Group ◽  
P Value ◽  
Healthy Control

Abstract Background and Aim: In this study FSH, LH, Testosterone, Estrogen, Progesterone serum levels in women affected by trigeminal neuralgia have been evaluated.Materials and Methods: This study is a cross sectional study during 2017-2018 in which FSH, LH, Testosterone, Estrogen, Progesterone serum levels in women affected by trigeminal neuralgia, who had referred to Emam Reza clinic and Oral and Maxillofacial Disease Department of Shiraz Dental Faculty, have been evaluated. Twenty-six women with trigeminal neuralgia were recruited in trigeminal neuralgia(TN) group and 26 healthy women whom their age were matched with TN group were enrolled in the healthy control group. Data was analyzed by SPSS version 18.Results: Sex hormone serum level was not significantly different between patients with TN and healthy control group (P value ≥0.05). In spite of this finding, the serum level of FSH in non-menopausal (P value=0.002) participants and progesterone in menopausal (P value=0.016) participants of TN and healthy control group, were significantly different. The serum level for both of these hormones were higher in patients with TN. In contrast to healthy control group, the sex hormone profiles of patients with TN, except LH did not follow the natural pattern changes based on menopausal status. Conclusion: In spite of no significant differences in sex hormonal profile of patients with TN and healthy controls, some hormonal disturbance in FSH and progesterone have been detected in TN patients in comparison between non-menopause and menopausal sex hormones profile.

scholarly journals C5n 5 55Detection of Some Immunological Parameters in Psoriatic Iraqi Female Patients

2020 ◽  
pp. 2515-2524
Author(s):  
Rehab Morad Khazem ◽  
Shaima R. Ibraheem
Keyword(s):  
Serum Levels ◽  
Interleukin 10 ◽  
Living Condition ◽  
Healthy Control Group ◽  
Control Group ◽  
Immunological Parameters ◽  
Female Patients ◽  
Healthy Control ◽  
The Mean ◽  
Severity Of The Disease

Psoriasis is a common, chronic, immune-mediated skin disease with systemic pro-inflammatory activation.  This study was designed to estimate the level of two cytokines, Interleukin-36 (IL-36) and Interleukin-10 (IL-10), in psoriasis female patients. The study was accomplished on 50 Iraqi patients with psoriasis who were referred to the consulting clinic at Al-Yarmouk Teaching Hospital during the period from November 2018 to March 2019. These patients were diagnosed under the supervision of dermatologists. For the purpose of comparison, the study included 30 healthy women as a healthy control group. The serum levels of cytokines  were measured using the enzyme-linked immunosorbent technique (ELISA).The results of this study showed that the mean age of the female patients was 35.9 ± 1.85 years, whereas the age of the patients with a severity of higher than 30% ranged 15-25 years. Most of the patients were married, in an average living condition, and non-smokers, and their menstrual cycle was continuous. It was also found that 28% of the psoriatic patients had other chronic diseases. The study showed statistically significant differences (p <0.05) in the mean level of IL-36 between the patients and healthy control group, whereas there was no statistical difference in the mean level of IL-10. In conclusion,   the   decrease in the level of IL-36 in the patients might be related to the increase in the severity of the disease.

Evaluation of serum microRNA expression profile in panic disorder patients

2017 ◽  
Vol 41 (S1) ◽  
pp. S595-S595
Author(s):  
F.P. Çökmüş ◽  
E. Özmen ◽  
T. Alkın ◽  
M.B. Batır ◽  
F.S. Çam
Keyword(s):  
Panic Disorder ◽  
Mirna Expression ◽  
Venous Blood ◽  
Clinical Information ◽  
Serum Levels ◽  
Healthy Control Group ◽  
Control Group ◽  
Receptor Subtypes ◽  
Expression Levels ◽  
Healthy Control

IntroductionEven though it has begun to be investigated in recent years, studies of microRNA (miRNA) in anxiety disorders are limited. Our research is the first miRNA expression study in panic disorder, which excludes of drug use and additional psychiatric disorders.ObjectiveWe aimed to determine the availability of miRNAs as biomarkers in the serum levels of panic disorder and to demonstrate the changing expression of miRNAs.MethodsIn the research, 35 panic disorder patients and 35 healthy controls were administered a socio-demographic and clinical information form, SCID-I, PDSS. 2 tubes of peripheral venous blood were taken from each group for genetic evaluation. miRNA expression analysis was performed in those samples by the RT-PCR method.ResultsCompared with the healthy control group, 8 miRNA expression levels were found different in panic disorder group. Five of them were up-regulated and 3 of them were down-regulated. There was no correlation between the level of miRNA expression and PDSS total score and PDSS sub-items. miR-1297 and miR-4465 expression levels were statistically significant between the two groups. Both miRNAs are also known to arrange the gene regions that affect GABAA receptor subtypes.ConclusionsmiR-1297 and miR-4465 regulate the GABAA gene that is thought to play a role in the etiology of panic disorder (Wong et al., 2014, Wang 2016). In panic disorder group, miR-1297 and miR-4465 expression levels were found to be up-regulated from the healthy control group.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Low Serum Galectin-1 Levels Predict Future Lymphoma Development in HIV-Positive Patients

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2945-2945
Author(s):  
Maja Ludvigsen ◽  
Maja Ølholm Vase ◽  
Rikke Hjortebjerg ◽  
Irma Petruskevicius ◽  
Court Pedersen ◽  
...  
Keyword(s):  
Serum Levels ◽  
Healthy Control Group ◽  
Control Group ◽  
Hiv Diagnosis ◽  
Hiv Patients ◽  
Lower Serum ◽  
Advisory Boards ◽  
Increased Risk ◽  
Healthy Control

Abstract Introduction. HIV infected individuals have an increased risk of developing lymphoma compared to sex- and age matched non-immunocompromised control population and approximately 2% of HIV infected individuals developed lymphoma (Gopal et al, J Natl cancer Inst 2013). Our group has been among the first who identified novel serum protein markers present at time of HIV diagnosis, which were predictive of subsequent lymphoma development (Vase et al, AIDS 2016). Galectins are important regulators of cell adhesion, apoptosis, cell cycle, and mRNA processing. Galectin-1 (Gal-1) is a known lectin-binding protein able to mediate Th2 skewed microenvironment in lymphomas (Juszczynski et al, Proc Natl Acad Sci U S A 2007; Cedeno-Laurent et al, Blood 2012), and facilitates HIV-infection (Sato et al, Ann N Y Acad Sci 2012). Increased serum Gal-1 levels were correlated to increased tumor burden and adverse clinical features in Hodgkin lymphoma (HL) (Kamper et al, Blood 2011; Ouyang et al, Blood 2013) and low Gal-1 levels were associated with an increased risk of chronic graft-versus-host disease in patients with hematologic malignancies treated with non-myeloablative hematopoietic stem cell transplantation (Petruskevicius et al, BMT 2016). In this study, we investigated whether the serum level of Gal-1 at the time of HIV diagnosis was predictive for subsequent lymphoma development. Methods. We determined the serum levels of Gal-1 in serum samples from19 HIV infected patients collected at the time of HIV diagnosis. Measurements were performed using a time-resolved immunofluorometric assay, as previously described (Petruskevicius et al, BMT 2016). Patients were grouped based on clinical outcomes in (i) future HIV-associated lymphoma (HIV/lymphoma), (ii) future HIV-associated benign lymphadenopathy (HIV/adenopathy), and (iii) no future neoplasia (HIV/no neoplasia), Table 1. Furthermore, serum Gal-1 levels were compared to those of a healthy control group (n=30), as previously reported (Petruskevicius et al, BMT 2016). Gal-1 sample concentrations were calculated by regression anaysis on basis of a standard curve of recombinant Gal-1 at concentrations of 100 to 0.78 ng/mL with 1:4 sample dilutions. Gal-1 levels > 400ng/mL was included in the analyses with a value of 400ng/mL. Estimates of differences between groups were evaluated using Student's t-test or ANOVA on log transformed data. A ROC analysis was computed to establish cut-off values for serum galectin-1, with respect to development of lymphoma. Results. Overall, the serum Gal-1 level in the HIV cohort was lower than in the healthy control group (p<0.001), Figure 1A. At HIV diagnosis, those HIV patients who would subsequently develop lymphoma had significantly lower levels of serum Gal-1 compared to the remaining cohort, Figure 1B (p=0.017). There was no gender-related difference (p=0.436) and Gal-1 serum levels did not correlate with either CD4 count (p=0.553) or viral load (p=0.600) at time of HIV diagnosis. In this size-limited study population, it was not possible to show any significant difference between HIV/lymphoma, HIV/adenopathy, and HIV/no neoplasia. ROC calculated cut-off of 2.6 ng/mL was able to separate HIV patients with future lymphoma from the remaining HIV patients and controls with a specificity of 78% and sensitivity of 100%. At this cut-off 13 (31%) patients were allocated to the low Gal-1 group, including all future lymphoma patients. Conclusion. HIV infected patients had significant lower serum Gal-1 levels than compared to a healthy control cohort. All HIV infected patients that later developed lymphoma belonged to the subset with lowest serum Gal-1 levels. If confirmed in independent cohorts of HIV patients from the cART era, this observation will support the use of low serum levels of Gal-1 as an early predictive biomarker for subsequent lymphoma development in HIV infected individuals. This may in turn have potential implications on the clinical monitoring strategy of these patients. Table 1 Characteristics of HIV patients in the serum galectin-1 study *Time before lymphoma or day of follow up (death or study end) Table 1. Characteristics of HIV patients in the serum galectin-1 study. / *Time before lymphoma or day of follow up (death or study end) Figure 1 Serum levels of Gal-1. A: Serum Gal-1 levels in the HIV cohort (n=19) were significant lower than in the healthy control group (n=30). B: At HIV diagnosis, significant lower serum Gal-1 levels was observed in HIV-patients with future lymphoma diagnosis (n=5) compared to the remaining cohort (n=44). Figure 1. Serum levels of Gal-1. A: Serum Gal-1 levels in the HIV cohort (n=19) were significant lower than in the healthy control group (n=30). B: At HIV diagnosis, significant lower serum Gal-1 levels was observed in HIV-patients with future lymphoma diagnosis (n=5) compared to the remaining cohort (n=44). Disclosures d'Amore: Servier: Honoraria, Other: Advisory Boards; CTI LIfe Sciences: Honoraria, Other: Advisory Boards.

scholarly journals Correlation between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Ahmed Al-Qahtani ◽  
Mashael Al-Anazi ◽  
Ayman A. Abdo ◽  
Faisal M. Sanai ◽  
Waleed Al-Hamoudi ◽  
...  
Keyword(s):  
Serum Level ◽  
Disease Progression ◽  
Serum Levels ◽  
Control Group ◽  
Nucleotide Polymorphisms ◽  
Virus Genotype ◽  
Interleukin 28B ◽  
Virus Genotypes ◽  
Healthy Control ◽  
Chronic Hcv

Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients. The aim of the study was to correlate the serum level of IL28B in HCV-infected patients with virus genotype/subgenotype and disease progression. IL28B serum level was detected and variations at five single nucleotide polymorphisms (SNPs) in IL28B gene region were genotyped and analyzed. The variation of IL28B genetic polymorphisms was found to be strongly associated with HCV infection when healthy control group was compared to HCV-infected patients with allPvalues <0.0001. Functional analysis revealed that subjects carrying rs8099917-GG genotype had higher serum level of IL28B than those with GT or TT genotypes(P=0.04). Also, patients who were presented with cirrhosis (Cirr) only or with cirrhosis plus hepatocellular carcinoma (Cirr+HCC) had higher levels of serum IL28B when compared to chronic HCV-infected patients (P=0.005and 0.003, resp.). No significant association was found when serum levels of IL28B were compared to virus genotypes/subgenotypes. This study indicates that variation at SNP rs8099917 could predict the serum levels of IL28B in HCV-infected patients. Furthermore, IL28B serum level may serve as a useful marker for the development of HCV-associated sequelae.

scholarly journals Detection of Epstein Barr Virus Infection in Reactive Arthritis Patients

2020 ◽  
pp. 2479-2485
Author(s):  
Ola Hafedh Nsaif Al-Bayati ◽  
Walaa Najm Abood ◽  
Dunya Fareed Salloom
Keyword(s):  
Reactive Arthritis ◽  
Joint Inflammation ◽  
Serum Levels ◽  
Molecular Study ◽  
Healthy Control Group ◽  
Control Group ◽  
Epstein Barr Virus Infection ◽  
Barr Virus ◽  
Healthy Control ◽  
Epstein Barr

Reactive arthritis (ReA) is an incendiary joint inflammation that occurs few days to weeks after a gastrointestinal or genitourinary infection. The etiology of the disease is not well-known. Therefore, the present study included 80 females and 25 males, divided into 51 patients with reactive arthritis and 54 healthy individuals as control group.  The study involved the detection of serum levels of anti-rheumatoid factor and anti-cyclic citrullinated peptide antibodies (anti-CCP) as well as those of CRP and C3 in all subjects. In addition, EBV levels were detected by Real Time-PCR technique. The results showed significantly increased levels (P < 0.05) of CRP, C3 and anti-CCP Ab in ReA patients’ group compared to the healthy control group (505.42 ± 402.94 versus 255.62 ± 135.5 U/ml, 61.20 ± 100.64 versus 20.43 ± 47.63 ng/ml and 35.11 ± 30.0 versus 6.82 ± 14.01 pg/ml, respectively), Also, the RF results demonstrated a significantly increased percentage in ReA patients’ group compared to a healthy control group (61.11 versus 37.25 %). While, the molecular study showed a non-significant increase in the percentage of EBV in ReA patients’ group compared to a healthy control group (17.65 versus 12.69 %). The results of this study lead to suggest that the immunological markers used may play a role in the development of ReA disease, while there was a non-significant association between EBV infection and ReA disease development.

CLINICO-HEMATOLOGICAL STUDY OF ACUTE LYMPHOBLASTIC LEUKEMIA AND THEIR CORRELATION WITH INFLAMMATORY MARKERS IN SERUM.

2021 ◽  
pp. 6-12
Author(s):  
Kavyanjali Sharma ◽  
Usha Usha ◽  
Vijai Tilak ◽  
Vineeta Gupta ◽  
Madhukar Rai ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Elevated Serum ◽  
Serum Levels ◽  
Healthy Control Group ◽  
Control Group ◽  
Male Predominance ◽  
Healthy Control ◽  
Bleeding Manifestation

SUMMARY: Acute lymphoblastic leukemia (ALL) is early childhood hematological malignancies. In present scenario immunophenotyping became an important tool for subtyping of ALL into B-ALL and TALL. In order to understand the mechanism of development of leukemia it is important to study the cytokine environment of malignant cells. OBJECTIVE: Aim of the present study was to evaluate clinical and hematological features in ALL and correlate serum levels of IL6 and IL-10 expression in ALL patients and their subtypes. MATERIALS & METHODS: A total of 68 ALL cases along with 20 healthy controls were included in the study between periods of 2015 to 2017. About 4 mL blood samples were collected from all cases for immunophenotyping and serum studies. Levels of IL6 and IL10 were determined in all cases by ELISA. RESULT: In the present study immunphenotyping was done in all cases of ALL, which showed 52 cases (76.5%) of B-ALL and 16 cases (23.5%) of T-ALL. T-ALL was mostly found in higher aged children than B-ALL. A male predominance was seen in all cases. No signicant differences in hemoglobin levels and platelet counts were found between T-ALL and B-ALL. A signicantly high percentage of T-ALL cases were having more than 50000 cells per microliter than B-ALL (56.2% vs. 23.1%). Almost similar clinical features were found in both subgroups, only bleeding manifestation was found signicantly higher in T-ALL than B-ALL (31.2% vs.11.5%). Acute lymphoblastic leukemia (ALL) patients were associated with signicantly elevated serum IL6 and IL10 level than the healthy control group. Mean levels of serum IL6 were 167.9±306.46 pg/mL in ALL, and 6.51 ± 2.27 pg/mL in healthy control group. Mean IL10 levels were 70.56±111.48 pg/mL in ALL and 29.39 ± 4.27 pg/mL in control group. There were no signicant differences found in IL-6 and IL-10 serum levels between T-ALL and B-ALL. CONCLUSION: Present study found elevated level of IL-6 and IL-10 in ALL patients which suggest possible role of these cytokines in disease transformation. Detection of IL-6 and IL-10 in newly diagnosed patient may predict disease outcome and possibly poor prognosis in patients

Vitamin D Treatment in Patients with Hashimoto’s Thyroiditis may Decrease the Development of Hypothyroidism

2016 ◽  
Vol 86 (1-2) ◽  
pp. 9-17 ◽  
Author(s):  
Bekir Ucan ◽  
Mustafa Sahin ◽  
Muyesser Sayki Arslan ◽  
Nujen Colak Bozkurt ◽  
Muhammed Kizilgul ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Hashimoto’S Thyroiditis ◽  
Healthy Control Group ◽  
Hashimoto's Thyroiditis ◽  
Control Group ◽  
Endocrine Society ◽  
Thyroid Autoantibody ◽  
Healthy Control ◽  
The Mean

Abstract.The relationship between Hashimoto’s thyroiditis and vitamin D has been demonstrated in several studies. The aim of the present study was to evaluate vitamin D concentrations in patients with Hashimoto’s thyroiditis, the effect of vitamin D therapy on the course of disease, and to determine changes in thyroid autoantibody status and cardiovascular risk after vitamin D therapy. We included 75 patients with Hashimoto’s thyroiditis and 43 healthy individuals. Vitamin D deficiency is defined as a 25-hydroxy vitamin D (25(OH)D3) concentration less than 20ng/mL. Vitamin D deficient patients were given 50.000 units of 25(OH)D3 weekly for eight weeks in accordance with the Endocrine Society guidelines. All evaluations were repeated after 2 months of treatment. Patients with Hashimoto’s thyroiditis had significantly lower vitamin D concentrations compared with the controls (9.37±0.69 ng/mL vs 11.95±1.01 ng/mL, p < 0.05, respectively). Thyroid autoantibodies were significantly decreased by vitamin D replacement treatment in patients with euthyroid Hashimoto’s thyroiditis. Also, HDL cholesterol concentrations improved in the euthyroid Hashimoto group after treatment. The mean free thyroxine (fT4) concentrations were 0.89±0.02 ng/dL in patients with Hashimoto’s thyroiditis and 1.07±0.03 ng/dL in the healthy control group (p < 0.001). The mean thyroid volumes were 7.71±0.44 mL in patients with Hashimoto’s thyroiditis and 5.46±0.63 mL in the healthy control group (p < 0.01). Vitamin D deficiency is frequent in Hashimoto’s thyroiditis and treatment of patients with this condition with Vitamin D may slow down the course of development of hypothyroidism and also decrease cardiovascular risks in these patients. Vitamin D measurement and replacement may be critical in these patients.

Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients

2020 ◽  
Vol 22 (9) ◽  
pp. 657-662 ◽  
Author(s):  
Mustafa Celik ◽  
Alper Şen ◽  
İsmail Koyuncu ◽  
Ataman Gönel
Keyword(s):  
Amino Acids ◽  
Amino Acid ◽  
Free Amino Acid ◽  
Free Amino ◽  
Nasal Polyposis ◽  
Amino Acid Profile ◽  
Healthy Control Group ◽  
Control Group ◽  
Healthy Control ◽  
History Of

Aim and Objective:: To determine the mechanisms present in the etiopathogenesis of nasal polyposis. It is not clear whether amino acids contribute in a causal way to the development of the disease. Therefore, the aim of this study was to determine the plasma-free amino acid profile in patients with nasal polyposis and to compare the results with a healthy control group. Materials and Methods:: This was a prospective controlled study that took place in the Otolaryngology Department at the Harran University Faculty of Medicine between April 2017 and April 2018. Plasmafree amino acid profile levels were studied in serum samples taken from a patient group and a healthy control group. Patients who were diagnosed with bilateral diffuse nasal polyposis and were scheduled for surgical interventions were included in this study. Individuals whose age, gender, and body mass index values were compatible with that of the patient group and who did not have any health problems were included in the control group. All the participants whose levels of plasma-free amino acid were thought to be affected by one or more of the following factors were excluded from the study: smoking and alcohol use, allergic rhinitis presence, the presence of acute or chronic sinusitis, a history of endoscopic sinus surgery, unilateral nasal masses, a history of chronic drug use, systemic or topical steroid use in the last three months for any reason, and liver, kidney, hematological, cardiovascular, metabolic, neurological, or psychiatric disorders or malignancies. Results: In patients with nasal polyposis, 3-methyl histidine (3-MHIS: nasal polyposis group (ng) = 3.22 (1.92 – 6.07); control group (cg) = 1.21 (0.77 – 1.68); p = 0.001); arginine (arg: ng = 98.95 (70.81 – 117.75); cg = 75.10 (54.49 – 79.88); p = 0.005); asparagine (asn: ng = 79.84 (57.50 – 101.44); cg = 60.66 (46.39 – 74.62); p = 0.021); citrulline (cit: ng = 51.83 (43.81 – 59.78); cg = 38.33 (27.81 – 53.73); p = 0.038); cystine (cys: ng = 4.29 (2.43 – 6.66); cg = 2.41 (1.51 – 4.16); p = 0.019); glutamic acid (glu: ng = 234.86 (128.75 – 286.66); cg = 152.37 (122.51 – 188.34); p = 0.045); histidine (his: ng = 94.19 (79.34 – 113.99); cg = 74.80 (62.76 – 98.91); p = 0.018); lysine (lys: ng = 297.22 (206.55 – 371.25); cg = 179.50 (151.58 – 238.02); p = 0.001); ornithine (ng = 160.62 (128.36 – 189.32); cg = 115.91 (97.03 – 159.91); p = 0.019); serine (ser: ng = 195.15 (151.58 – 253.07); cg = 83.07 (67.44 – 92.44); p = 0.001); taurine (tau: ng = 74.69 (47.00 – 112.13); cg = 53.14 (33.57 – 67.31); p = 0.006); tryptophan (trp: ng = 52.31 (33.81 – 80.11); cg = 34.44 (25.94 – 43.07); p = 0.005), homocitrulline (ng = 1.75 (1.27 – 2.59); cg = 0.00 (0.00 – 0.53); p = 0.001); norvaline (ng = 6.90 (5.61 – 9.18); cg = 4.93 (3.74 – 7.13); p = 0.021); argininosuccinic acid (ng = 14.33 (10.06 – 25.65); cg = 12.22 (5.77 – 16.87) p = 0.046); and plasma concentrations were significantly higher than in the healthy control group (p <0.05). However, the gamma-aminobutyric acid (gaba: ng = 0.16 (0.10 – 0.24); cg = 0.21 (0.19 – 0.29); p = 0.010) plasma concentration was significantly lower in the nasal polyposis group than in the healthy control group. Conclusion: In this study, plasma levels of 15 free amino acids were significantly higher in the nasal polyposis group than in the healthy control group. A plasma level of 1 free amino acid was found to be significantly lower in the nasal polyposis group compared to the healthy control group. Therefore, it is important to determine the possibility of using the information obtained to prevent the recurrence of the condition and to develop effective treatment strategies. This study may be a milestone for studies of this subject. However, this study needs to be confirmed by further studies conducted in a larger series.

scholarly journals Correlation analysis of epicardial adipose tissue thickness, C-reactive protein, interleukin-6, visfatin, juxtaposed with another zinc finger protein 1, and type 2 diabetic macroangiopathy

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Yuan-Yuan Gong ◽  
Hai-Ying Peng
Keyword(s):  
Correlation Analysis ◽  
Zinc Finger Protein ◽  
Pearson Correlation ◽  
Statistical Significance ◽  
Healthy Control Group ◽  
Control Group ◽  
Diabetes Group ◽  
Reactive Protein ◽  
Healthy Control

Abstract Background To investigate the correlation between the thickness of epicardial adipose tissue (EAT), C-reactive protein (CRP), interleukin (IL) -6, visfatin, juxtaposed with another zinc finger protein 1 (JAZF1) and type 2 diabetic mellitus (T2DM) macroangiopathy. Methods The study enrolled 82 patients with T2DM with macroangiopathy (the Complication Group), and 85 patients with T2DM (the Diabetes Group) who were admitted to Shandong Provincial Third Hospital from February 2018 to February 2020. In addition, 90 healthy people who underwent physical examination at the same hospital during the same period were enrolled (the Healthy Control Group). Age, gender, height, weight, waist circumference (WC), hip circumference (HC), diabetic course and therapeutic drugs, waist hip ratio (WHR), and body mass index (BMI) were recorded and calculated. Results The baseline characteristics of the three groups were comparable, and the diabetic course of the Complication Group and the Diabetes Group was not significantly different (P > 0.05). The WHR of the Complication Group was higher than that of the Diabetes Group and the Healthy Control Group, with statistical significance (P < 0.05). The FPG, 2hPG, HbA1C, CRP, IL-6, Visfatin, JAZF1, HOMA-IR, EAT thickness, and baPWV of the Complication Group were all higher than those of the Diabetes Group and the Healthy Control Group (P < 0.05, respectively). The JAZF1 and FIns of the Complication Group and Diabetes Group were lower than those of the Healthy Control Group, and JAZF1 of the Complication Group was lower than the Diabetes Group with statistical significance (P<0.05, respectively). Pearson correlation analysis showed that the EAT thickness was positively correlated with CRP, IL-6, visfatin, and JAZF1 (r = 0.387, 0.451, 0.283, 0.301, respectively, all P<0.001). Pearson correlation analysis showed that baPWV was positively correlated with EAT thickness, CRP, IL-6, visfatin, and JAZF1 (r = 0.293, 0.382, 0.473, 0.286, respectively, all P < 0.001). Multivariate stepwise regression analysis showed that FPG, 2hPG, HbA1C, CRP, IL-6, visfatin, JAZF1, and EAT thickness were independent risk factors that affected T2DM macroangiopathy. Conclusions Clinical monitoring and treatment of T2DM macroangiopathy can use CRP, IL-6, Visfatin, JAZF1, and EAT thickness as new targets to delay the progression of the disease. Further research on the relationship between the above factors and the pathogenesis of T2DM macroangiopathy may be helpful provide new treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document